Date: 2015-02-23
Type of information: Nomination
Compound:
Company: Alkermes (Ireland)
Therapeutic area: CNS diseases - Neurodegenerative diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: * On February 23, 2015, Alkermes announced that it has appointed Mark Namchuk , Ph.D., as Senior Vice President of Research, Pharmaceutical and Nonclinical Development . Dr. Namchuk will be responsible for advancing the company\'s early-stage product pipeline. He will serve on the executive management team of Alkermes and report to Elliot Ehrich , M.D., Senior Vice President of Research & Development and Chief Medical Officer. Dr. Namchuk joins Alkermes with nearly 20 years of experience in integrated R&D and drug discovery. Most recently, Dr. Namchuk served as Senior Vice President and Interim Global Head of Research for Vertex Pharmaceuticals , leading a group of more than 450 researchers in the discovery of transformational medicines in the areas of infectious disease, oncology, inflammatory diseases, neurology and cystic fibrosis. He has built and led departments supporting the critical components of early pharmaceutical R&D, including medicinal chemistry, protein biophysics, in vitro and in vivo pharmacology, drug metabolism, pharmacokinetics, and clinical and preclinical biomarkers. Earlier in his career, he served as the head of the biochemistry group at Cubist Pharmaceuticals . Dr. Namchuk obtained his doctorate in bioorganic chemistry from the University of British Columbia and completed a post-doctoral fellowship at the University of California, San Francisco .
Financial terms:
Latest news:
